XML 44 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock Options
12 Months Ended
Dec. 31, 2017
Stock Options [Abstract]  
STOCK OPTIONS

7. STOCK OPTIONS

  

On January 31, 2007, the Board of Directors adopted our 2007 Omnibus Equity Compensation Plan (the “2007 Plan”), with 210,000 common shares authorized for issuance under the Plan. In October 2009, the Company’s stockholders approved an increase in the number of shares covered by the Plan to 420,000 shares. On March 26, 2015, the Board adopted our 2015 Omnibus Equity Compensation Plan (the “2015 Plan”), with 400,000 common shares authorized for issuance under the 2015 Plan, which was ratified by the Company’s stockholders on September 15, 2015. The 2007 Plan and 2015 Plan are collectively referred to as the “Plans.” Grants under the Plans may consist of incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, stock unit awards, dividend equivalents and other stock based awards. Employees, directors and consultants and other service providers are eligible to participate in the Plans. Options granted under the Plans vest over periods ranging from immediately upon grant to a three year period and expire ten years from date of grant. Employees, directors and consultants and other service providers are eligible to participate in the Plan. Options granted under the plan vest over periods ranging from immediately upon grant to a three year period and expire ten years from date of grant.

 

Activity in stock options for the year ended December 31, 2017 follows: 

 

  Number of
options
  Weighted
average
exercise
price
  Weighted
average
contractual
term 
(years)
  Aggregate
intrinsic
value
 
Outstanding at January 1, 2016  406,700  $8.50         
Granted  70,700   5.70         
Forfeited  (40,800)  6.70         
Exercised  (25,000) 1.70         
Outstanding at December 31, 2016  411,600  8.63         
Granted  106,000   4.24         
Forfeited  (16,700)  6.01         
Expired  (160,000)  12.50         
Exercised  (5,000)  3.00         
Outstanding at December 31, 2017  335,900  $5.61   7.19  $52,500 
Vested and exercisable at December 31, 2017  212,500  $6.27   6.01  $52,500 
Vested and exercisable at December 31, 2017 and expected to vest thereafter  331,600  $5.61   7.19  $52.500 

 

The weighted average grant date fair value of options granted during 2016 and 2017 was $2.03 and $1.65 per share respectively. The Company measured the fair value of each option award on the date of grant using the Black Scholes option pricing model (BSM) with the following assumptions:

 

  2016  2017 
Exercise price $4.90 to $6.60  $4.02 to$ 5.25 
Expected life  5.5 years   5.8 years 
Expected volatility  38%  38%
Dividend yield  0%  0%
Risk-free interest rate  1.13% to 1.73%  1.89% to 2.06%

  

The expected dividend yield is based on the Company’s historical dividend yield. The expected volatility was based on the average of historical volatilities for a period comparable to the expected life of the options of certain entities considered to be similar to the Company. The expected life is based on the simplified expected term calculation permitted by the SEC which defines the expected life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. The risk-free interest rate is based on the annual yield on the grant date of a zero-coupon U.S. Treasury bond the maturity of which equals the option’s expected life.

 

The value of stock options is recognized as compensation expense by the straight line method over the vesting period. Compensation expense recorded for options in the statements of operations was $113,952 and $136,308 for the years ended December 31, 2017 and 2016, respectively. Unrecognized compensation cost related to non-vested options at December 31, 2017 amounted to $128,781 which is expected to be recognized over a weighted average period of 2.12 years.